Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VRd followed by cilta-cel versus VRd followed by Rd in newly diagnosed multiple myeloma not planned for upfront transplant
MOH_2021-11-04_010155Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression prevention / progression-free comparison. Started Jul 2021; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucelbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2021-11-04_010155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-04_010155.